A new and simple blood test has been found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London.
In combination with the current prostate specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment.
Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide. It is currently detected using a blood test that measures PSA levels. Although it provides early diagnosis, the PSA blood test has a low specificity (high false positives) with about 75 per cent of all PSA positive results ending up with negative biopsies that do not find cancer.
When a high PSA level in the blood is detected, the patient undergoes a tissue biopsy of the prostate gland, which is invasive and carries a significant risk of bleeding and infection. On biopsy, the majority of patients with elevated PSA levels are found not to have cancer.
Additionally, most diagnosed early-stage prostate cancers are not fatal if left untreated. The current practice of the combined PSA test and biopsy for prostate cancer therefore results in unnecessary biopsies and over-diagnosis and overtreatment of many men.
Circulating tumor cells
The new prostate cancer test (the Parsortix® system from ANGLE plc) detects early cancer cells, or circulating tumor cells (CTCs), that have left the original tumour and entered the bloodstream prior to spreading around the body. By measuring intact living cancer cells in the patient’s blood, rather than the PSA protein which may be present in the blood for reasons other than cancer, it potentially provides a more accurate test for prostate cancer.
The study, published in the Journal of Urology, looked at the use of the CTC test in 98 pre-biopsy patients and 155 newly diagnosed prostate cancer patients enrolled at St Bartholomew’s Hospital in London.
The research team found that the presence of CTCs in pre-biopsy blood samples were indicative of the presence of aggressive prostate cancer, and efficiently and non-invasively predicted the later outcome of biopsy results.
When the CTC tests were used in combination with the current PSA test, it was able to predict the presence of aggressive prostate cancer in subsequent biopsies with over 90 per cent accuracy, better than any previously reported biomarkers.
Additionally, the number and type of CTCs present in the blood was also indicative of the aggressiveness of the cancer. Focusing on more aggressive prostate cancer may reduce over-treatment and unnecessary biopsies for benign and non-aggressive conditions.
‘A paradigm shift in the way we diagnose prostate cancer’
Lead researcher Professor Yong-Jie Lu from Queen Mary’s Barts Cancer Institute said: “The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and overtreatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for better selection of patients to undergo the biopsy procedure.
“Testing for circulating tumour cells is efficient, non-invasive and potentially accurate, and we’ve now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer.”
As this is a single centre study, the results need to be further validated in other independent research centres before the CTC test is available either privately or on the NHS in the UK, which could take a further 3-5 years. Clearance by the US Food and Drug Administration could also take 3-5 years.
Learn more: New blood test for prostate cancer is highly-accurate and avoids invasive biopsies
The Latest on: Prostate cancer
[google_news title=”” keyword=”prostate cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Prostate cancer
- London Health Science Foundation receives $1M gift for prostate cancer careon June 7, 2023 at 11:56 am
The large donation from Lexus of London will go towards supporting the creating and operation of a cancer biobank at London Health Sciences Centre (LHSC).
- FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate canceron June 7, 2023 at 11:40 am
The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, ...
- FDA clears Lynparza for prostate cancer treatmenton June 7, 2023 at 6:09 am
The Food and Drug Administration cleared a new cancer-fighting drug called Lynparza for prostate cancer treatment.
- Best Hospitals for Prostate Cancer Surgery in Jacksonville, FLon June 6, 2023 at 6:21 pm
Search hospitals in Jacksonville, FL that treat Prostate Cancer Surgery to find the best hospital for you.
- Can You Get a CT Scan for Prostate Cancer?on June 6, 2023 at 3:47 pm
Doctors do not usually use CT scans to diagnose prostate cancer, but they sometimes use them to see whether cancer has spread to other tissues. The survival rate of prostate cancer tends to be very ...
- Prostate cancer Warning Signs: What to Look Out Foron June 6, 2023 at 2:28 pm
OverviewA cancer of the prostate gland, a part of the male reproductive system. Prostate is a small walnut-shaped gland in males that produces the seminal fluid that nourishes and transports sperm.
- The Witcher Geralt of Rivia voice actor diagnosed with prostate canceron June 6, 2023 at 2:18 pm
Doug Cockle, the voice actor for Geralt and several other video game characters, has revealed that he has prostate cancer.
- What Is Active Surveillance for Prostate Cancer?on June 6, 2023 at 12:32 pm
Doctors often recommend monitoring slow-growing prostate cancer with regular tests instead of starting treatment right away. This is called active surveillance. Most types of prostate cancer tend to ...
- Researchers work to make prostate-specific antigen test for cancer more accurateon June 5, 2023 at 7:30 am
Researchers think they've found a way to make the blood test for prostate-specific antigen (PSA) accurate enough to significantly reduce overdiagnosis and better predict dangerous cancers.
- Improving prostate cancer screening: accounting for genetic determinants of PSA variationon June 5, 2023 at 5:42 am
Researchers conducted a genome-wide analysis of prostate-specific antigen (PSA) levels of men without prostate cancer.
via Bing News